2020DiabetesRequires access

23-LB: Overexpression of microRNA-16 Derepresses the Mitochondrial Function to Exacerbate Cardiomyopathy in Streptozotocin-Induced Diabetic Mice

Jing Zhou, Yinghong Zhu, Jing Fan

Open publisher page 1 citations

Abstract

Introduction: Diabetic cardiomyopathy is initially characterized by myocardial fibrosis, dysfunctional remodeling, and associated diastolic dysfunction, later by systolic dysfunction, and eventually by clinical heart failure. MicroRNAs (miRNAs), the endogenous small non-coding RNAs, were recognized to play significant roles in diabetes. But, it remains unknown whether mitochondrial function is modulated by miRNAs during diabetic cardiomyopathy. Aim: This study investigates the potential role of microRNA-16 (miR-16) in modulating mitochondrial function during diabetic cardiomyopathy. Methods and Results: To assess the function of miR-16 in vivo, miR-16 was expressed using a adeno-associated virus serotype 9 (AAV9) viral vector in male 1-week-old mice C57BL/6J mice. At 6-week-old, these mice received three consecutive daily i.p. injections of STZ (55 mg/kg body weight) combined with 18 weeks of high-fat diet to induce T2DM. We demonstrated that miR-16 expression was slight increased in diabetic mice. Overexpression of miR-16 exacerbated diabetic cardiomyopathy which reflected by increasing myocardial fibrosis and displaying a diastolic dysfunction in STZ-induced mice. Impaired mitochondrial function was observed in electron microscopy of myocardium in mice with overexpression of miR-16. In vitro, high glucose (HG) treated cultured cardiomyocytes with overexpression miR-16 showed a worse mitochondrial damage, and inhibition of miR-16 induced a protective effects role in HG-treated cardiomyocytes. Molecular mechanisms linked to the underlying pathophysiological changes include abnormalities in AMP-activated protein kinase, p38 MAPK and PGC1α. Conclusions: In conclusion, our results show that miR-16 plays an important role in the development of diabetic cardiomyopathy in T2DM mice, which can be targeted for therapeutic intervention. Disclosure J. Zhou: None. Y. Zhu: None. J. Fan: None.

About this research paper

What this paper is about

Introduction: Diabetic cardiomyopathy is initially characterized by myocardial fibrosis, dysfunctional remodeling, and associated diastolic dysfunction, later by systolic dysfunction, and eventually by clinical heart failure. MicroRNAs (miRNAs), the endogenous small non-coding RNAs, were recognized to play significant roles in diabetes. But, it remains unknown whether mitochondrial function is modulated by miRNAs during diabetic cardiomyopathy. Aim: This study investigates the potential role of microRNA-16 (miR-16) in modulating mitochondrial function during diabetic cardiomyopathy. Methods and Results: To assess the function of miR-16 in vivo, miR-16 was expressed using a adeno-associated virus serotype 9 (AAV9) viral vector in male 1-week-old mice C57BL/6J mice. At 6-week-old, these mice received three consecutive daily i.p. injections of STZ (55 mg/kg body weight) combined with 18 weeks of high-fat diet to induce T2DM. We demonstrated that miR-16 expression was slight increased in diabetic mice. Overexpression of miR-16 exacerbated diabetic cardiomyopathy which reflected by increasing myocardial fibrosis and displaying a diastolic dysfunction in STZ-induced mice. Impaired mitochondrial function was observed in electron microscopy of myocardium in mice with overexpression of miR-16. In vitro, high glucose (HG) treated cultured cardiomyocytes with overexpression miR-16 showed a worse mitochondrial damage, and inhibition of miR-16 induced a protective effects role in HG-treated cardiomyocytes. Molecular mechanisms linked to the underlying pathophysiological changes include abnormalities in AMP-activated protein kinase, p38 MAPK and PGC1α. Conclusions: In conclusion, our results show that miR-16 plays an important role in the development of diabetic cardiomyopathy in T2DM mice, which can be targeted for therapeutic intervention. Disclosure J. Zhou: None. Y. Zhu: None. J. Fan: None.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction: Diabetic cardiomyopathy is initially characterized by myocardial fibrosis, dysfunctional remodeling, and associated diastolic dysfunction, later by systolic dysfunction, and eventually by clinical heart failure. MicroRNAs (miRNAs), the endogenous small non-coding RNAs, were recognized to play significant roles in diabetes. But, it remains unknown whether mitochondrial function is modulated by miRNAs during diabetic cardiomyopathy. Aim: This study investigates the potential role of microRNA-16 (miR-16) in modulating mitochondrial function during diabetic cardiomyopathy. Methods and Results: To assess the function of miR-16 in vivo, miR-16 was expressed using a adeno-associated virus serotype 9 (AAV9) viral vector in male 1-week-old mice C57BL/6J mice. At 6-week-old, these mice received three consecutive daily i.p. injections of STZ (55 mg/kg body weight) combined with 18 weeks of high-fat diet to induce T2DM. We demonstrated that miR-16 expression was slight increased in diabetic mice. Overexpression of miR-16 exacerbated diabetic cardiomyopathy which reflected by increasing myocardial fibrosis and displaying a diastolic dysfunction in STZ-induced mice. Impaired mitochondrial function was observed in electron microscopy of myocardium in mice with overexpression of miR-16. In vitro, high glucose (HG) treated cultured cardiomyocytes with overexpression miR-16 showed a worse mitochondrial damage, and inhibition of miR-16 induced a protective effects role in HG-treated cardiomyocytes. Molecular mechanisms linked to the underlying pathophysiological changes include abnormalities in AMP-activated protein kinase, p38 MAPK and PGC1α. Conclusions: In conclusion, our results show that miR-16 plays an important role in the development of diabetic cardiomyopathy in T2DM mice, which can be targeted for therapeutic intervention. Disclosure J. Zhou: None. Y. Zhu: None. J. Fan: None.

Key concepts: Diabetic cardiomyopathy, Cardiomyopathy, Streptozotocin, Internal medicine, Endocrinology, Cardiac function curve, Medicine, Diabetes mellitus

Related papers

Back to paper searchBrowse research topicsOriginal source
23-LB: Overexpression of microRNA-16 Derepresses the Mitochondrial Function to Exacerbate Cardiomyopathy in Streptozotocin-Induced Diabetic Mice — Research Paper | ScholarLens